Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Antonio Jimeno

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-2478

    Collapse Research 
    Collapse research activities and funding
    R21DE019712     (JIMENO, ANTONIO)Sep 1, 2009 - Aug 31, 2012
    NIH/NIDCR
    Rational generation of a head and neck squamous cell cancer direct xenograft mode
    Role: Principal Investigator
    R01CA149456     (JIMENO, ANTONIO)Aug 9, 2010 - May 31, 2022
    NIH/NCI
    Characterizing the regulation of PD-1 ligands in head and neck cancer stem cells using an autologous humanized model with T cell education capability
    Role: Principal Investigator
    R21CA156114     (JIMENO, ANTONIO)Sep 8, 2011 - Aug 31, 2014
    NIH/NCI
    Rational combination of EGFR and Hedgehog inhibitors in head and neck cancer
    Role: Principal Investigator
    R56DE023245     (REYLAND, MARY ELAINE)Sep 26, 2012 - Aug 31, 2014
    NIH/NIDCR
    Functional characterization of salivary gland cancers and development of patient
    Role: Co-Principal Investigator
    R01DE024371     (WANG, XIAO-JING)Aug 1, 2014 - Jul 31, 2018
    NIH/NIDCR
    Identifying oral cancer stem cell properties affected by the microenvironment
    Role: Co-Principal Investigator
    R01CA213102     (JIMENO, ANTONIO)Aug 1, 2017 - Jul 31, 2020
    NIH/NCI
    Development of an autologous humanized model of melanoma exploring human thymic education capacity
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2018 Sep 19. PMID: 30229512.
      View in: PubMed
    2. Morton JJ, Keysar SB, Perrenoud L, Chimed TS, Reisinger J, Jackson B, Le PN, Nieto C, Gomez K, Miller B, Gao D, Somerset H, Wang XJ, Jimeno A. Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer. Mol Carcinog. 2018 Aug 21. PMID: 30129680.
      View in: PubMed
    3. Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, Aisner DL, Bowles DW, Raben D. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018 Jul 03. PMID: 30084837.
      View in: PubMed
    4. Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018 Jun 21. PMID: 29931076.
      View in: PubMed
    5. Bhatia S, Sharma J, Bukkapatnam S, Oweida A, Lennon S, Phan A, Milner D, Uyanga N, Jimeno A, Raben D, Somerset H, Heasley L, Karam SD. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers. Clin Cancer Res. 2018 Sep 15; 24(18):4539-4550. PMID: 29848571.
      View in: PubMed
    6. Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw. 2018 May; 16(5):479-490. PMID: 29752322.
      View in: PubMed
    7. Keysar SB, Eagles JR, Miller B, Jackson BC, Chowdhury FN, Reisinger J, Chimed TS, Le PN, Morton JJ, Somerset HL, Varella-Garcia M, Tan AC, Song JI, Bowles DW, Reyland ME, Jimeno A. Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. Clin Cancer Res. 2018 Jun 15; 24(12):2935-2943. PMID: 29555661.
      View in: PubMed
    8. Sharma P, King GT, Shinde SS, Purev E, Jimeno A. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas. Drugs Today (Barc). 2018 Mar; 54(3):187-198. PMID: 29771253.
      View in: PubMed
    9. King GT, Sharma P, Davis SL, Jimeno A. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy. Drugs Today (Barc). 2018 Feb; 54(2):103-122. PMID: 29637937.
      View in: PubMed
    10. Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. 2018 May; 185:122-134. PMID: 29269044.
      View in: PubMed
    11. Dionne LK, Peterman E, Schiel J, Gibieža P, Skeberdis VA, Jimeno A, Wang XJ, Prekeris R. FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation. J Cell Sci. 2017 Dec 01; 130(23):4051-4062. PMID: 29196475.
      View in: PubMed
    12. Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2018 Jan; 17(1):215-221. PMID: 29054986.
      View in: PubMed
    13. Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Dec 15; 23(24):7490-7497. PMID: 28954784.
      View in: PubMed
    14. Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2018 Mar; 25(3):768-775. PMID: 28887726.
      View in: PubMed
    15. Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017 06; 15(6):761-770. PMID: 28596256.
      View in: PubMed
    16. Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017 07 01; 77(13):3551-3563. PMID: 28428274.
      View in: PubMed
    17. Rusthoven CG, Lanning RM, Jones BL, Amini A, Koshy M, Sher DJ, Bowles DW, McDermott JD, Jimeno A, Karam SD. Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol. 2017 07; 124(1):139-146. PMID: 28433411.
      View in: PubMed
    18. Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight. 2017 Mar 23; 2(6):e90449. PMID: 28352657.
      View in: PubMed
    19. Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 08; 35(4):471-477. PMID: 28105566.
      View in: PubMed
    20. Bhatia S, Hirsch K, Sharma J, Oweida A, Griego A, Keysar S, Jimeno A, Raben D, Krasnoperov V, Gill PS, Pasquale EB, Wang XJ, Karam SD. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. Sci Rep. 2016 12 12; 6:38792. PMID: 27941840.
      View in: PubMed
    21. Jian Z, Strait A, Jimeno A, Wang XJ. Cancer Stem Cells in Squamous Cell Carcinoma. J Invest Dermatol. 2017 01; 137(1):31-37. PMID: 27638386.
      View in: PubMed
    22. Oweida A, Bhatia S, Hirsch K, Calame D, Griego A, Keysar S, Pitts T, Sharma J, Eckhardt G, Jimeno A, Wang XJ, Parkash G, Califano J, Karam SD. Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors. Mol Carcinog. 2017 03; 56(3):1189-1196. PMID: 27649287.
      View in: PubMed
    23. Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB. Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol. 2016; 6:232. PMID: 27843803.
      View in: PubMed
    24. Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Dec 01; 122(23):3641-3649. PMID: 27648727.
      View in: PubMed
    25. Keysar SB, Le PN, Miller B, Jackson BC, Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, Padilla-Just N, Gomez K, Warnock E, Reisinger J, Arcaroli JJ, Messersmith WA, Wakefield LM, Gao D, Tan AC, Serracino H, Vasiliou V, Roop DR, Wang XJ, Jimeno A. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. J Natl Cancer Inst. 2017 01; 109(1). PMID: 27634934.
      View in: PubMed
    26. Morton JJ, Bird G, Refaeli Y, Jimeno A. Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. Cancer Res. 2016 11 01; 76(21):6153-6158. PMID: 27587540.
      View in: PubMed
    27. Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Dec 15; 122(24):3803-3811. PMID: 27525588.
      View in: PubMed
    28. Gan GN, Jimeno A. Emerging from their burrow: Hedgehog pathway inhibitors for cancer. Expert Opin Investig Drugs. 2016 Oct; 25(10):1153-66. PMID: 27459882.
      View in: PubMed
    29. Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Green JA, Steer C, Berns EM, Casado A, Lambrechts D, Jimeno A. Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2016 Jun; 11(3):429. PMID: 27056749.
      View in: PubMed
    30. Bowles DW, Kochenderfer M, Cohn A, Sideris L, Nguyen N, Cline-Burkhardt V, Schnadig I, Choi M, Nabell L, Chaudhry A, Ruxer R, Ucar A, Hausman D, Walker L, Spira A, Jimeno A. A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clin Colorectal Cancer. 2016 12; 15(4):337-344.e2. PMID: 27118441.
      View in: PubMed
    31. Amini A, Jasem J, Jones BL, Robin TP, McDermott JD, Bhatia S, Raben D, Jimeno A, Bowles DW, Karam SD. Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base. Oral Oncol. 2016 May; 56:1-7. PMID: 27086480.
      View in: PubMed
    32. Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, Ghosh D, Bowles DW, Karam SD. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer. 2016 05 15; 122(10):1533-43. PMID: 26969811.
      View in: PubMed
    33. Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT. Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. J Clin Pharmacol. 2016 08; 56(8):966-73. PMID: 26632033; PMCID: PMC4892995 [Available on 08/01/17].
      View in: PubMed, PubMed Central
    34. Bornstein E, Jimeno A. Olaparib for the treatment of ovarian cancer. Drugs Today (Barc). 2016 Jan; 52(1):17-28. PMID: 26937492.
      View in: PubMed
    35. Gan GN, Altunbas C, Morton JJ, Eagles J, Backus J, Dzingle W, Raben D, Jimeno A. Radiation dose uncertainty and correction for a mouse orthotopic and xenograft irradiation model. Int J Radiat Biol. 2016; 92(1):50-6. PMID: 26689828; PMCID: PMC4750646 [Available on 01/01/17].
      View in: PubMed, PubMed Central
    36. Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb; 53:74-9. PMID: 26705064.
      View in: PubMed
    37. Allen CP, Tinganelli W, Sharma N, Nie J, Sicard C, Natale F, King M, Keysar SB, Jimeno A, Furusawa Y, Okayasu R, Fujimori A, Durante M, Nickoloff JA. DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation. Front Oncol. 2015; 5:260. PMID: 26697402; PMCID: PMC4670845.
      View in: PubMed, PubMed Central
    38. Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2015 Dec; 10(4):583-96. PMID: 26004768; PMCID: PMC4661131 [Available on 12/01/16].
      View in: PubMed, PubMed Central
    39. Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Oct; 5(10):1049-57. PMID: 26216294; PMCID: PMC4635026.
      View in: PubMed, PubMed Central
    40. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer. 2016 Jan 01; 138(1):195-205. PMID: 26152787; PMCID: PMC4618491.
      View in: PubMed, PubMed Central
    41. Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Jul; 13(7):847-55; quiz 856. PMID: 26150579; PMCID: PMC4976490.
      View in: PubMed, PubMed Central
    42. Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 2016 Mar; 38(3):439-47. PMID: 25352401; PMCID: PMC4414661.
      View in: PubMed, PubMed Central
    43. Noonan S, Man Wong K, Jimeno A. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer. Drugs Today (Barc). 2015 Jun; 51(6):357-66. PMID: 26261849.
      View in: PubMed
    44. Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2462-70. PMID: 26034219.
      View in: PubMed
    45. Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clin Cancer Res. 2015 Oct 01; 21(19):4356-64. PMID: 26015511; PMCID: PMC4592392 [Available on 10/01/16].
      View in: PubMed, PubMed Central
    46. Singh S, Arcaroli J, Chen Y, Thompson DC, Messersmith W, Jimeno A, Vasiliou V. ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/ß-Catenin, Notch and PI3K/Akt Signaling Pathways. PLoS One. 2015; 10(5):e0121648. PMID: 25950950; PMCID: PMC4423958.
      View in: PubMed, PubMed Central
    47. Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE. An Inducible TGF-ß2-TGFßR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. PLoS One. 2015; 10(5):e0123600. PMID: 25946135.
      View in: PubMed
    48. Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, Glogowska MJ, Estes P, Eagles JR, Le PN, Gan G, McGettigan B, Fernandez P, Padilla-Just N, Varella-Garcia M, Song JI, Bowles DW, Schedin P, Tan AC, Roop DR, Wang XJ, Refaeli Y, Jimeno A. XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene. 2016 Jan 21; 35(3):290-300. PMID: 25893296; PMCID: PMC4613815.
      View in: PubMed, PubMed Central
    49. Klopper J, Kane M, Jimeno A, Sams S, French J, Pike L, Tompkins K, Haugen B. A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer. Thyroid. 2015 May; 25(5):563-4. PMID: 25778496; PMCID: PMC4426316.
      View in: PubMed, PubMed Central
    50. Wong KM, Noonan S, O'Bryant C, Jimeno A. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer. Drugs Today (Barc). 2015 Mar; 51(3):161-70. PMID: 25876560.
      View in: PubMed
    51. Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Jun 15; 21(12):2695-703. PMID: 25724527.
      View in: PubMed
    52. Jimeno A, Bauman JE, Weissman C, Adkins D, Schnadig I, Beauregard P, Bowles DW, Spira A, Levy B, Seetharamu N, Hausman D, Walker L, Rudin CM, Shirai K. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncol. 2015 Apr; 51(4):383-8. PMID: 25593016; PMCID: PMC4857706.
      View in: PubMed, PubMed Central
    53. Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 01; 21(7):1566-73. PMID: 25573383.
      View in: PubMed
    54. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc). 2015 Jan; 51(1):7-20. PMID: 25685857.
      View in: PubMed
    55. Jimeno A, Shirai K, Choi M, Laskin J, Kochenderfer M, Spira A, Cline-Burkhardt V, Winquist E, Hausman D, Walker L, Cohen RB. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann Oncol. 2015 Mar; 26(3):556-61. PMID: 25524478.
      View in: PubMed
    56. Gan GN, Eagles J, Keysar SB, Wang G, Glogowska MJ, Altunbas C, Anderson RT, Le PN, Morton JJ, Frederick B, Raben D, Wang XJ, Jimeno A. Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers. Cancer Res. 2014 Dec 01; 74(23):7024-36. PMID: 25297633; PMCID: PMC4253591.
      View in: PubMed, PubMed Central
    57. Amini A, McDermott JD, Gan G, Bhatia S, Sumner W, Fisher CM, Jimeno A, Bowles DW, Raben D, Karam SD. Stereotactic body radiotherapy as primary therapy for head and neck cancer in the elderly or patients with poor performance. Front Oncol. 2014; 4:274. PMID: 25340041; PMCID: PMC4189612.
      View in: PubMed, PubMed Central
    58. Scott A, Messersmith WA, Jimeno A, Davies SL. Panitumumab in the treatment of colon cancer: A biomarker dilemma. Drugs Today (Barc). 2014 Oct; 50(10):679-90. PMID: 25374966.
      View in: PubMed
    59. Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014 Oct; 12(10):1454-87. PMID: 25313184.
      View in: PubMed
    60. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral ?-secretase inhibitor PF-03084014. Clin Cancer Res. 2015 Jan 01; 21(1):60-7. PMID: 25231399.
      View in: PubMed
    61. Bird GA, Polsky A, Estes P, Hanlon T, Hamilton H, Morton JJ, Gutman J, Jimeno A, Turner BC, Refaeli Y. Expansion of human and murine hematopoietic stem and progenitor cells ex vivo without genetic modification using MYC and Bcl-2 fusion proteins. PLoS One. 2014; 9(8):e105525. PMID: 25170611; PMCID: PMC4149411.
      View in: PubMed, PubMed Central
    62. Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther. 2015 Feb; 146:1-11. PMID: 25172549; PMCID: PMC4304994.
      View in: PubMed, PubMed Central
    63. Vergote I, Coens C, Casado A, Jimeno A. Reply to B. Freidlin et al. J Clin Oncol. 2014 Aug 01; 32(22):2388. PMID: 24982455.
      View in: PubMed
    64. Bowles DW, Senzer N, Hausman D, Peterson S, Vo A, Walker L, Cohen RB, Jimeno A. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2014 Dec; 32(6):1197-203. PMID: 24916771.
      View in: PubMed
    65. McDermott J, Jimeno A. Belinostat for the treatment of peripheral T-cell lymphomas. Drugs Today (Barc). 2014 May; 50(5):337-45. PMID: 24918834.
      View in: PubMed
    66. Bowles DW, McDermott JD, Jimeno A. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. Future Oncol. 2014 May; 10(6):1065-80. PMID: 24941990.
      View in: PubMed
    67. McDermott J, Jimeno A. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. Drugs Today (Barc). 2014 Apr; 50(4):291-300. PMID: 24918646.
      View in: PubMed
    68. Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1656-65. PMID: 24493827; PMCID: PMC4160109.
      View in: PubMed, PubMed Central
    69. Lopez JP, Jimeno A. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma. Drugs Today (Barc). 2014 Feb; 50(2):113-20. PMID: 24619588.
      View in: PubMed
    70. Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol. 2014 Feb 01; 32(4):320-6. PMID: 24366937.
      View in: PubMed
    71. White RA, Neiman JM, Reddi A, Han G, Birlea S, Mitra D, Dionne L, Fernandez P, Murao K, Bian L, Keysar SB, Goldstein NB, Song N, Bornstein S, Han Z, Lu X, Wisell J, Li F, Song J, Lu SL, Jimeno A, Roop DR, Wang XJ. Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. J Clin Invest. 2013 Oct; 123(10):4390-404. PMID: 23999427.
      View in: PubMed
    72. Bowles DW, Weickhardt A, Jimeno A. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. Drugs Today (Barc). 2013 Sep; 49(9):523-35. PMID: 24086949.
      View in: PubMed
    73. Alluri N, Jimeno A. Trametinib for the treatment of melanoma. Drugs Today (Barc). 2013 Aug; 49(8):491-8. PMID: 23977666.
      View in: PubMed
    74. Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt D, Takimoto SM, Aisner DL, Wilhelm F, Frederick BA, Varella-Garcia M, Tan AC, Jimeno A. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther. 2013 Oct; 12(10):1994-2005. PMID: 23873848; PMCID: PMC3796006.
      View in: PubMed, PubMed Central
    75. Narayanan V, Gutman JA, Pollyea DA, Jimeno A. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. Drugs Today (Barc). 2013 Jul; 49(7):447-56. PMID: 23914353.
      View in: PubMed
    76. Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A. Tivozanib: practical implications for renal cell carcinoma and other solid tumors. Drugs Today (Barc). 2013 May; 49(5):303-15. PMID: 23724410.
      View in: PubMed
    77. Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013 May 15; 19(10):2766-74. PMID: 23575478; PMCID: PMC3694426.
      View in: PubMed, PubMed Central
    78. Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 2013 Jun 01; 73(11):3381-92. PMID: 23576557; PMCID: PMC3674118.
      View in: PubMed, PubMed Central
    79. Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013 Aug; 7(4):776-90. PMID: 23607916; PMCID: PMC3760013.
      View in: PubMed, PubMed Central
    80. Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Drugs Today (Barc). 2013 Apr; 49(4):261-9. PMID: 23616953.
      View in: PubMed
    81. Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, Kamiyama M, Schuler FW, Lin MT, Beaty RM, Karanam B, Liang H, Mullendore ME, Mo G, Hidalgo M, Jaffee E, Hruban RH, Jinnah HA, Roden RB, Jimeno A, Liu JO, Maitra A, Eshleman JR. Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res. 2013 Mar 01; 19(5):1139-46. PMID: 23340293; PMCID: PMC3612923.
      View in: PubMed, PubMed Central
    82. Psyrri A, Seiwert TY, Jimeno A. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book. 2013; 246-55. PMID: 23714515.
      View in: PubMed
    83. Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct; 48(10):633-44. PMID: 23110259.
      View in: PubMed
    84. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 01; 18(15):4173-82. PMID: 22693357.
      View in: PubMed
    85. Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs. 2012 Dec; 30(6):2391-9. PMID: 22547163; PMCID: PMC3557459.
      View in: PubMed, PubMed Central
    86. Harry BL, Eckhardt SG, Jimeno A. JAK2 inhibition for the treatment of hematologic and solid malignancies. Expert Opin Investig Drugs. 2012 May; 21(5):637-55. PMID: 22493978.
      View in: PubMed
    87. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012 Apr 17; 9(6):338-50. PMID: 22508028; PMCID: PMC3928688.
      View in: PubMed, PubMed Central
    88. Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A. Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Drugs Today (Barc). 2012 Apr; 48(4):271-82. PMID: 22536569.
      View in: PubMed
    89. Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res. 2012 Apr 01; 18(7):2048-55. PMID: 22338014.
      View in: PubMed
    90. Weiss GJ, Hidalgo M, Borad MJ, Laheru D, Tibes R, Ramanathan RK, Blaydorn L, Jameson G, Jimeno A, Isaacs JD, Scaburri A, Pacciarini MA, Fiorentini F, Ciomei M, Von Hoff DD. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2012 Dec; 30(6):2334-43. PMID: 22160853; PMCID: PMC3561458.
      View in: PubMed, PubMed Central
    91. Minor J, Wang X, Zhang F, Song J, Jimeno A, Wang XJ, Lu X, Gross N, Kulesz-Martin M, Wang D, Lu SL. Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. Oral Oncol. 2012 Jan; 48(1):73-8. PMID: 22133638; PMCID: PMC3291120.
      View in: PubMed, PubMed Central
    92. Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc). 2011 Nov; 47(11):857-68. PMID: 22146228.
      View in: PubMed
    93. Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol. 2012 Jul; 83(1):1-10. PMID: 22019199.
      View in: PubMed
    94. Bowles DW, Reddy K, Wine T, Ree A, Raben D, Chen C, Jimeno A. Locoregional recurrence of an HPV-positive squamous cell carcinoma of the head and neck. Oncology (Williston Park). 2011 Oct; 25(11):1042-8. PMID: 22106555.
      View in: PubMed
    95. Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Sep 01; 17(17):5774-82. PMID: 21753154.
      View in: PubMed
    96. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5793-800. PMID: 21742805; PMCID: PMC3210576.
      View in: PubMed, PubMed Central
    97. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O'Sullivan B, He Z, Peng Y, Tan AC, Zhou L, Shen J, Han G, Wang XJ, Thorburn J, Thorburn A, Jimeno A, Raben D, Bedford JS, Li CY. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011 Jul 03; 17(7):860-6. PMID: 21725296; PMCID: PMC3132290.
      View in: PubMed, PubMed Central
    98. Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs. 2011 Apr; 20(4):507-18. PMID: 21395485.
      View in: PubMed
    99. Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J, Colomer R, Cortés-Funes H, Jimeno A. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol. 2011 Mar; 13(3):179-84. PMID: 21421462.
      View in: PubMed
    100. Khachatryan V, Sirunyan AM, Tumasyan A, Adam W, Bergauer T, Dragicevic M, Erö J, Fabjan C, Friedl M, Frühwirth R, Ghete VM, Hammer J, Hänsel S, Hartl C, Hoch M, Hörmann N, Hrubec J, Jeitler M, Kasieczka G, Kiesenhofer W, Krammer M, Liko D, Mikulec I, Pernicka M, Rohringer H, Schöfbeck R, Strauss J, Taurok A, Teischinger F, Waltenberger W, Walzel G, Widl E, Wulz CE, Mossolov V, Shumeiko N, Gonzalez JS, Benucci L, Ceard L, De Wolf EA, Janssen X, Maes T, Mucibello L, Ochesanu S, Roland B, Rougny R, Selvaggi M, Van Haevermaet H, Van Mechelen P, Van Remortel N, Adler V, Beauceron S, Blyweert S, D'Hondt J, Devroede O, Kalogeropoulos A, Maes J, Maes M, Tavernier S, Van Doninck W, Van Mulders P, Van Onsem GP, Villella I, Charaf O, Clerbaux B, De Lentdecker G, Dero V, Gay AP, Hammad GH, Hreus T, Marage PE, Thomas L, Vander Velde C, Vanlaer P, Wickens J, Costantini S, Grunewald M, Klein B, Marinov A, Ryckbosch D, Thyssen F, Tytgat M, Vanelderen L, Verwilligen P, Walsh S, Zaganidis N, Basegmez S, Bruno G, Caudron J, De Favereau De Jeneret J, Delaere C, Demin P, Favart D, Giammanco A, Grégoire G, Hollar J, Lemaitre V, Militaru O, Ovyn S, Pagano D, Pin A, Piotrzkowski K, Quertenmont L, Schul N, Beliy N, Caebergs T, Daubie E, Alves GA, De JesusDamiao D, Pol ME, Souza MH, Carvalho W, Da Costa EM, Martins Cde O, De Souza SF, Mundim L, Nogima H, Oguri V, Goicochea JM, Da Silva WL, Santoro A, Do Amaral SM, Sznajder A, De Araujo FT, Dias FA, Dias MA, Tomei TR, Gregores EM, Marinho F, Novaes SF, Padula SS, Darmenov N, Dimitrov L, Genchev V, Iaydjiev P, Piperov S, Rodozov M, Stoykova S, Sultanov G, Tcholakov V, Trayanov R, Vankov I, Dyulendarova M, Hadjiiska R, Kozhuharov V, Litov L, Marinova E, Mateev M, Pavlov B, Petkov P, Bian JG, Chen GM, Chen HS, Jiang CH, Liang D, Liang S, Wang J, Wang J, Wang X, Wang Z, Yang M, Zang J, Zhang Z, Ban Y, Guo S, Hu Z, Li W, Mao Y, Qian SJ, Teng H, Zhu B, Cabrera A, Moreno BG, Rios AA, Oliveros AF, Sanabria JC, Godinovic N, Lelas D, Lelas K, Plestina R, Polic D, Puljak I, Antunovic Z, Dzelalija M, Brigljevic V, Duric S, Kadija K, Morovic S, Attikis A, Fereos R, Galanti M, Mousa J, Nicolaou C, Ptochos F, Razis PA, Rykaczewski H, Abdel-basit A, Assran Y, Mahmoud MA, Hektor A, Kadastik M, Kannike K, Müntel M, Raidal M, Rebane L, Azzolini V, Eerola P, Czellar S, Härkönen J, Heikkinen A, Karimäki V, Kinnunen R, Klem J, Kortelainen MJ, Lampén T, Lassila-Perini K, Lehti S, Lindén T, Luukka P, Mäenpää T, Tuominen E, Tuominiemi J, Tuovinen E, Ungaro D, Wendland L, Banzuzi K, Korpela A, Tuuva T, Sillou D, Besancon M, Dejardin M, Denegri D, Fabbro B, Faure JL, Ferri F, Ganjour S, Gentit FX, Givernaud A, Gras P, de Monchenault GH, Jarry P, Locci E, Malcles J, Marionneau M, Millischer L, Rander J, Rosowsky A, Titov M, Verrecchia P, Baffioni S, Bianchini L, Bluj M, Broutin C, Busson P, Charlot C, Dobrzynski L, de Cassagnac RG, Haguenauer M, Miné P, Mironov C, Ochando C, Paganini P, Sabes D, Salerno R, Sirois Y, Thiebaux C, Wyslouch B, Zabi A, Agram JL, Andrea J, Besson A, Bloch D, Bodin D, Brom JM, Cardaci M, Chabert EC, Collard C, Conte E, Drouhin F, Ferro C, Fontaine JC, Gelé D, Goerlach U, Greder S, Juillot P, Karim M, Le Bihan AC, Mikami Y, Van Hove P, Fassi F, Mercier D, Baty C, Beaupere N, Bedjidian M, Bondu O, Boudoul G, Boumediene D, Brun H, Chanon N, Chierici R, Contardo D, Depasse P, El Mamouni H, Falkiewicz A, Fay J, Gascon S, Ille B, Kurca T, Le Grand T, Lethuillier M, Mirabito L, Perries S, Sordini V, Tosi S, Tschudi Y, Verdier P, Xiao H, Roinishvili V, Anagnostou G, Edelhoff M, Feld L, Heracleous N, Hindrichs O, Jussen R, Klein K, Merz J, Mohr N, Ostapchuk A, Perieanu A, Raupach F, Sammet J, Schael S, Sprenger D, Weber H, Weber M, Wittmer B, Ata M, Bender W, Erdmann M, Frangenheim J, Hebbeker T, Hinzmann A, Hoepfner K, Hof C, Klimkovich T, Klingebiel D, Kreuzer P, Lanske D, Magass C, Masetti G, Merschmeyer M, Meyer A, Papacz P, Pieta H, Reithler H, Schmitz SA, Sonnenschein L, Steggemann J, Teyssier D, et al. Search for quark compositeness with the dijet centrality ratio in pp collisions at vs=7 TeV. Phys Rev Lett. 2010 Dec 31; 105(26):262001. PMID: 21231646.
      View in: PubMed
    101. Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec; 9(5):297-304. PMID: 21208844; PMCID: PMC3033228.
      View in: PubMed, PubMed Central
    102. Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol. 2010 Dec 01; 3(6):373-9. PMID: 21151476; PMCID: PMC3000462.
      View in: PubMed, PubMed Central
    103. Keysar SB, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther. 2010 Sep; 9(9):2450-7. PMID: 20716638; PMCID: PMC3618879.
      View in: PubMed, PubMed Central
    104. Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3057-66. PMID: 20501622; PMCID: PMC3035576.
      View in: PubMed, PubMed Central
    105. Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs. 2011 Oct; 29(5):1057-65. PMID: 20306339; PMCID: PMC3110647.
      View in: PubMed, PubMed Central
    106. Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1020-5. PMID: 20231078.
      View in: PubMed
    107. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A, Hidalgo M, Maitra A, Matsui W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010 Mar 03; 102(5):340-51. PMID: 20164446; PMCID: PMC2831049.
      View in: PubMed, PubMed Central
    108. Jimeno A, Rubio-Viqueira B, Rajeshkumar NV, Chan A, Solomon A, Hidalgo M. A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb; 9(2):311-8. PMID: 20103597.
      View in: PubMed
    109. Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A, Messersmith WA. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn. 2010 Jan; 12(1):43-50. PMID: 20007845; PMCID: PMC2797717.
      View in: PubMed, PubMed Central
    110. Diamond JR, Borges VF, Eckhardt SG, Jimeno A. BRCA in breast cancer: from risk assessment to therapeutic prediction. Drug News Perspect. 2009 Dec; 22(10):603-8. PMID: 20140280.
      View in: PubMed
    111. Gravalos C, Cassinello J, García-Alfonso P, Jimeno A. Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr; 74(1):16-26. PMID: 19616446.
      View in: PubMed
    112. Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: An update. Drugs Today (Barc). 2009 Jul; 45(7):521-32. PMID: 19834629.
      View in: PubMed
    113. Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, Warren MV, Walker J, Green TP, Jimeno A, Messersmith WA, Hidalgo M. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res. 2009 Jun 15; 15(12):4138-46. PMID: 19509160.
      View in: PubMed
    114. Jimeno A. Eribulin: rediscovering tubulin as an anticancer target. Clin Cancer Res. 2009 Jun 15; 15(12):3903-5. PMID: 19509144.
      View in: PubMed
    115. Messersmith WA, Rajeshkumar NV, Tan AC, Wang XF, Diesl V, Choe SE, Follettie M, Coughlin C, Boschelli F, Garcia-Garcia E, Lopez-Rios F, Jimeno A, Hidalgo M. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther. 2009 Jun; 8(6):1484-93. PMID: 19509264.
      View in: PubMed
    116. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol. 2009 Dec; 3(5-6):425-38. PMID: 19497796.
      View in: PubMed
    117. Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009 Jun 01; 27(16):2697-704. PMID: 19380450; PMCID: PMC2689846.
      View in: PubMed, PubMed Central
    118. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J. 2009 Mar-Apr; 15(2):110-3. PMID: 19390304.
      View in: PubMed
    119. Shabbeer S, Sobolewski M, Anchoori RK, Kachhap S, Hidalgo M, Jimeno A, Davidson N, Carducci MA, Khan SR. Fenugreek: a naturally occurring edible spice as an anticancer agent. Cancer Biol Ther. 2009 Feb; 8(3):272-8. PMID: 19197146; PMCID: PMC3095649.
      View in: PubMed, PubMed Central
    120. Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García E, López-Ríos F, Matsui W, Maitra A, Hidalgo M. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009 Feb; 8(2):310-4. PMID: 19174553; PMCID: PMC3033101.
      View in: PubMed, PubMed Central
    121. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 2009 Mar 01; 27(7):1130-6. PMID: 19124802.
      View in: PubMed
    122. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol. 2008 Dec 01; 26(34):5504-10. PMID: 18955447; PMCID: PMC4824307.
      View in: PubMed, PubMed Central
    123. Song D, Chaerkady R, Tan AC, García-García E, Nalli A, Suárez-Gauthier A, López-Ríos F, Zhang XF, Solomon A, Tong J, Read M, Fritz C, Jimeno A, Pandey A, Hidalgo M. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther. 2008 Oct; 7(10):3275-84. PMID: 18852131.
      View in: PubMed
    124. Harsha HC, Jimeno A, Molina H, Mihalas AB, Goggins MG, Hruban RH, Schulick RD, Kamath U, Maitra A, Hidalgo M, Pandey A. Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res. 2008 Nov; 7(11):4651-8. PMID: 18821783.
      View in: PubMed
    125. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26; 321(5897):1801-6. PMID: 18772397; PMCID: PMC2848990.
      View in: PubMed, PubMed Central
    126. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 01; 26(25):4172-9. PMID: 18757332; PMCID: PMC2654371.
      View in: PubMed, PubMed Central
    127. Laheru D, Croghan G, Bukowski R, Rudek M, Messersmith W, Erlichman C, Pelley R, Jimeno A, Donehower R, Boni J, Abbas R, Martins P, Zacharchuk C, Hidalgo M. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res. 2008 Sep 01; 14(17):5602-9. PMID: 18765554; PMCID: PMC3086427.
      View in: PubMed, PubMed Central
    128. Omura N, Li CP, Li A, Hong SM, Walter K, Jimeno A, Hidalgo M, Goggins M. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther. 2008 Jul; 7(7):1146-56. PMID: 18535405; PMCID: PMC2763640.
      View in: PubMed, PubMed Central
    129. Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA, Hidalgo M. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res. 2008 Apr 15; 68(8):2841-9. PMID: 18413752.
      View in: PubMed
    130. Messersmith WA, Jimeno A, Ettinger D, Laheru D, Brahmer J, Lansey D, Khan Y, Donehower RC, Elsayed Y, Zannikos P, Hidalgo M. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Dec; 63(1):181-8. PMID: 18379785; PMCID: PMC3556988.
      View in: PubMed, PubMed Central
    131. Ma WW, Jimeno A. Temsirolimus. Drugs Today (Barc). 2007 Oct; 43(10):659-69. PMID: 17987219.
      View in: PubMed
    132. Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza P, Krailo M, Ingle AM, Blaney SM, Adamson P, Hidalgo M. Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr Blood Cancer. 2007 Sep; 49(3):352-7. PMID: 16425266.
      View in: PubMed
    133. Li J, Zhao M, Jimeno A, He P, Ramana Reddy MV, Hidalgo M, Donehower RC, Rudek MA. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 01; 856(1-2):198-204. PMID: 17588831; PMCID: PMC4286291.
      View in: PubMed, PubMed Central
    134. Jimeno A, Hallur G, Chan A, Zhang X, Cusatis G, Chan F, Shah P, Chen R, Hamel E, Garrett-Mayer E, Khan S, Hidalgo M. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. Mol Cancer Ther. 2007 May; 6(5):1509-16. PMID: 17483439.
      View in: PubMed
    135. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol. 2008 Mar; 61(3):423-33. PMID: 17429623; PMCID: PMC3557498.
      View in: PubMed, PubMed Central
    136. Ma WW, Jimeno A. Strategies for suppressing angiogenesis in gynecological cancers. Drugs Today (Barc). 2007 Apr; 43(4):259-73. PMID: 17460787.
      View in: PubMed
    137. Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald V, Maitra A, Iacobuzio-Donahue C, Hidalgo M. Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol Cancer Ther. 2007 Mar; 6(3):1079-88. PMID: 17363501.
      View in: PubMed
    138. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, Gabrielson KL, Matsui W, Maitra A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007 Mar 01; 67(5):2187-96. PMID: 17332349; PMCID: PMC3073370.
      View in: PubMed, PubMed Central
    139. Rubio-Viqueira B, Mezzadra H, Nielsen ME, Jimeno A, Zhang X, Iacobuzio-Donahue C, Maitra A, Hidalgo M, Altiok S. Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Mol Cancer Ther. 2007 Feb; 6(2):515-23. PMID: 17308050.
      View in: PubMed
    140. Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M. Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther. 2006 Dec; 5(12):3240-7. PMID: 17172427.
      View in: PubMed
    141. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6296s-6300s. PMID: 17062717.
      View in: PubMed
    142. Jimeno A, Hidalgo M. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim Biophys Acta. 2006 Dec; 1766(2):217-29. PMID: 17045403.
      View in: PubMed
    143. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006 Aug 01; 12(15):4652-61. PMID: 16899615.
      View in: PubMed
    144. Quintela-Fandino M, López JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F, Cortés-Funes H. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol. 2006 Aug 01; 24(22):3611-8. PMID: 16877728.
      View in: PubMed
    145. Jimeno A, Hidalgo M. Multitargeted therapy: can promiscuity be praised in an era of political correctness? Crit Rev Oncol Hematol. 2006 Aug; 59(2):150-8. PMID: 16843676.
      View in: PubMed
    146. Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A, Nielsen ME, Maitra A, Altiok S. Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. Mol Cancer Ther. 2006 Jul; 5(7):1895-903. PMID: 16891476.
      View in: PubMed
    147. Jimeno A, Carducci M. Atrasentan: a rationally designed targeted therapy for cancer. Drugs Today (Barc). 2006 May; 42(5):299-312. PMID: 16801993.
      View in: PubMed
    148. Hallur G, Jimeno A, Dalrymple S, Zhu T, Jung MK, Hidalgo M, Isaacs JT, Sukumar S, Hamel E, Khan SR. Benzoylphenylurea sulfur analogues with potent antitumor activity. J Med Chem. 2006 Apr 06; 49(7):2357-60. PMID: 16570932.
      View in: PubMed
    149. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther. 2006 Apr; 5(4):787-96. PMID: 16648548.
      View in: PubMed
    150. Jimeno A, Kulesza P, Kincaid E, Bouaroud N, Chan A, Forastiere A, Brahmer J, Clark DP, Hidalgo M. C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res. 2006 Feb 15; 66(4):2385-90. PMID: 16489045.
      View in: PubMed
    151. Hitt R, Amador ML, Quintela-Fandino M, Jimeno A, del Val O, Hernando S, Cortes-Funes H. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer. 2006 Jan 01; 106(1):106-11. PMID: 16329139.
      View in: PubMed
    152. Messersmith W, Oppenheimer D, Peralba J, Sebastiani V, Amador M, Jimeno A, Embuscado E, Hidalgo M, Iacobuzio-Donahue C. Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biol Ther. 2005 Dec; 4(12):1381-6. PMID: 16319527.
      View in: PubMed
    153. Rudek MA, Zhao M, Smith NF, Robey RW, He P, Hallur G, Khan S, Hidalgo M, Jimeno A, Colevas AD, Messersmith WA, Wolff AC, Baker SD. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clin Cancer Res. 2005 Dec 01; 11(23):8503-11. PMID: 16322314.
      View in: PubMed
    154. Jimeno A, Hidalgo M. Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. Expert Rev Anticancer Ther. 2005 Aug; 5(4):727-35. PMID: 16111472.
      View in: PubMed
    155. Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther. 2005 Jun; 5(3):419-27. PMID: 16001950.
      View in: PubMed
    156. Zhao M, Hartke C, Jimeno A, Li J, He P, Zabelina Y, Hidalgo M, Baker SD. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 05; 819(1):73-80. PMID: 15797523.
      View in: PubMed
    157. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. 2005 Apr 15; 65(8):3003-10. PMID: 15833824.
      View in: PubMed
    158. Jimeno A. Race, gender and mutations in the prediction of anti-EGFR activity. Future Oncol. 2005 Apr; 1(2):201-4. PMID: 16555991.
      View in: PubMed
    159. Jimeno A, Hidalgo M. Blockade of epidermal growth factor receptor (EGFR) activity. Crit Rev Oncol Hematol. 2005 Mar; 53(3):179-92. PMID: 15718144.
      View in: PubMed
    160. Jimeno A, Hitt R, Quintela-Fandino M, Cortés-Funes H. Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. Anticancer Drugs. 2005 Jan; 16(1):53-7. PMID: 15613904.
      View in: PubMed
    161. Jimeno A, Carducci M. Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opin Investig Drugs. 2004 Dec; 13(12):1631-40. PMID: 15566319.
      View in: PubMed
    162. Hitt R, Jimeno A, Millán JM, Castellano D, Cortés-Funes H. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer. 2004 Aug 15; 101(4):768-75. PMID: 15305408.
      View in: PubMed
    163. Jimeno A, García-Velasco A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muñoz A, López-Martín A, Durán I, Robles L, Cortés-Funes H, Paz-Ares L. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004 Jun 01; 100(11):2462-9. PMID: 15160353.
      View in: PubMed
    164. Amador ML, Jimeno A, Hitt R, Cortés-Funes H, Colomer R. Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer: a retrospective analysis. Am J Clin Oncol. 2004 Jun; 27(3):269-73. PMID: 15170146.
      View in: PubMed
    165. Jimeno A, Amador ML, González-Cortijo L, Tornamira MV, Ropero S, Valentín V, Hornedo J, Cortés-Funes H, Colomer R. Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. Cancer. 2004 May 01; 100(9):1833-42. PMID: 15112263.
      View in: PubMed
    166. Hitt R, Jimeno A, Castellano D, Cortés-Funes H. Unusual response to gemcitabine in a case of peritoneal malignant fibrous histiocytoma. Anticancer Drugs. 2003 Sep; 14(8):663-4. PMID: 14501390.
      View in: PubMed
    167. Jimeno A, Ciruelos EM, Castellano D, Caballero B, Rodriguez-Peralto JL, Cortés-Funes H. Radiation recall dermatitis induced by pegylated liposomal doxorubicin. Anticancer Drugs. 2003 Aug; 14(7):575-6. PMID: 12960743.
      View in: PubMed
    Jimeno's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (533) concept(s)
    _
    Co-Authors Expand Description
    See all (75) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)